BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

575 related articles for article (PubMed ID: 32015021)

  • 1. Enhancing Chimeric Antigen Receptor T-Cell Efficacy in Solid Tumors.
    Fucà G; Reppel L; Landoni E; Savoldo B; Dotti G
    Clin Cancer Res; 2020 Jun; 26(11):2444-2451. PubMed ID: 32015021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
    Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions.
    Bagley SJ; O'Rourke DM
    Pharmacol Ther; 2020 Jan; 205():107419. PubMed ID: 31629009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
    Kosti P; Maher J; Arnold JN
    Front Immunol; 2018; 9():1104. PubMed ID: 29872437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineering CAR-T Cells for Next-Generation Cancer Therapy.
    Hong M; Clubb JD; Chen YY
    Cancer Cell; 2020 Oct; 38(4):473-488. PubMed ID: 32735779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric antigen receptor transduced T cells: Tuning up for the next generation.
    Schubert ML; Hoffmann JM; Dreger P; Müller-Tidow C; Schmitt M
    Int J Cancer; 2018 May; 142(9):1738-1747. PubMed ID: 29119551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CAR T Cell Therapy for Solid Tumors.
    Newick K; O'Brien S; Moon E; Albelda SM
    Annu Rev Med; 2017 Jan; 68():139-152. PubMed ID: 27860544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps.
    Beatty GL; O'Hara M
    Pharmacol Ther; 2016 Oct; 166():30-9. PubMed ID: 27373504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors.
    Jindal V; Arora E; Gupta S
    Med Oncol; 2018 May; 35(6):87. PubMed ID: 29730801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-tagging by oncolytic viruses: A novel strategy for CAR-T therapy against solid tumors.
    Tang XY; Ding YS; Zhou T; Wang X; Yang Y
    Cancer Lett; 2021 Apr; 503():69-74. PubMed ID: 33476650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
    Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The dilemmas and possible solutions for CAR-T cell therapy application in solid tumors.
    Wang L; Zhang L; Dunmall LC; Wang YY; Fan Z; Cheng Z; Wang Y
    Cancer Lett; 2024 Jun; 591():216871. PubMed ID: 38604310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CAR-T cell therapy in melanoma: A future success story?
    Simon B; Uslu U
    Exp Dermatol; 2018 Dec; 27(12):1315-1321. PubMed ID: 30288790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment.
    Liu G; Rui W; Zhao X; Lin X
    Cell Mol Immunol; 2021 May; 18(5):1085-1095. PubMed ID: 33785843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells.
    Gowrishankar K; Birtwistle L; Micklethwaite K
    Mamm Genome; 2018 Dec; 29(11-12):739-756. PubMed ID: 29987406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.
    Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
    Zhang E; Gu J; Xu H
    Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Solid Tumors Challenges and New Insights of CAR T Cell Engineering.
    Tahmasebi S; Elahi R; Esmaeilzadeh A
    Stem Cell Rev Rep; 2019 Oct; 15(5):619-636. PubMed ID: 31161552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?
    Wagner J; Wickman E; DeRenzo C; Gottschalk S
    Mol Ther; 2020 Nov; 28(11):2320-2339. PubMed ID: 32979309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.